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Abstract
Background: The pressure on healthcare services worldwide has driven the incorporation of disease state management
services within community pharmacies in developed countries. Pharmacists are recognised as the most accessible
healthcare professionals, and the incorporation of these services facilitates patient care. In Australia, the opportunity to
manage pharmacy patients with mental illness has been underutilised, despite the existence of service models for
other chronic conditions. This paper is an independent evaluation of a novel service developed by a community
pharmacy in Perth, Western Australia. The service represents collaboration between a nurse practitioner and
community pharmacy staff in the management of mental health patients with metabolic risks.
Methods: We applied practice service standards for Australian community pharmacies to develop an evaluation
framework for this novel service. This was followed by semi-structured interviews with staff members at the study
pharmacy to explore service processes and procedures. Descriptive analysis of interviews was supplemented with
analysis of patients’ biometric data. All data were evaluated against the developed framework.
Results: The evaluation framework comprised 13 process, 5 outcomes, and 11 quality indicators. Interview data
from eight staff members and biometric data from 20 community-dwelling mental health patients taking antipsychotics
were evaluated against the framework. Predominantly, patients were managed by the pharmacy’s nurse practitioner,
with medication management provided by pharmacists. Patients’ biometric measurements comprised weight, blood
pressure, blood glucose levels, lipid profiles and management of obesity, smoking, hypertension and diabetes. Positive
outcomes observed in the patient data included weight loss, smoking cessation, and improved blood pressure, blood
glucose and lipid levels.
Conclusions: The developed framework allowed effective evaluation of the service, and may be applicable to other
pharmacy services. The metabolic clinic met key process, quality and outcomes indicators. The positive patient
outcomes may assist in securing further funding.
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Background
Community pharmacists have, over recent decades, posi-
tioned themselves to provide disease state management
services to supplement patient management by other
healthcare providers (e.g. general practitioners). The value
of community pharmacy patient-centred disease-state man-
agement services has been evaluated in developed coun-
tries, with evidence of facilitated patient care and positive
patient outcomes [1–4]. Successful funded pilot projects
have resulted in service funding by various governments
[1–4]. In Australia, community pharmacists are recognised
as the most accessible health professionals, and hence are
ideally positioned to provide timely healthcare services to
patients [1].
The Australian Government has supported trials of
disease state management services that promote a role
for pharmacists in the management of chronic condi-
tions such as asthma [5], diabetes [6], hypertension [7]
and weight management [8], collectively developing a
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service model for collaborative management of chronic
conditions through pharmacies. Whilst these trials re-
ported positive outcomes for patients’ health, commit-
ment by participating pharmacists varied. These trials
involved the community pharmacist as the service pro-
vider, with referrals to other health professionals as
deemed necessary.
No published studies appear to have evaluated the
provision of chronic disease management services by other
healthcare professionals, such as nurse practitioners (NPs),
in community pharmacies. In Australia, a NP is a registered
nurse certified to operate independently and cooperatively
in a highly developed and extended clinical role. The role
of a NP comprises patient assessment and management
using nursing knowledge and skills. The role may include,
but is not limited to, referral of patients to other health
professionals, prescribing of certain government-subsidised
medications and ordering of pathology tests [9, 10].
Mental health management services are still under de-
velopment in Australian community pharmacy practice,
despite pharmacists’ skills in monitoring medicine adverse
effects and providing clinical interventions [11–13]. Men-
tal health conditions such as anxiety and depression are
common, with data showing approximately 50% of the
Australian population as likely to experience a diagnosable
mental health illness in their lifetime [14]. Management of
depression, schizophrenia and bipolar disorder, which
may require treatment with antidepressants or atypical
antipsychotic agents (e.g. olanzapine, clozapine, risperi-
done, quetiapine), necessitates a high level of monitor-
ing and multi-disciplinary collaboration. A number of
these medications are associated with co-morbidities in-
cluding weight gain, hyperglycaemia, hypertension and
dyslipidaemia [15, 16].
There is a dearth of information about the community
pharmacy management of patients taking antipsychotic
medicines, with specific reference to the patients’ meta-
bolic risk, and collaboration between pharmacists and
NPs. We have attempted to meet this need via evaluation
of a novel mental health service developed within a com-
munity pharmacy in Perth, Western Australia. One com-
ponent of this service is a metabolic clinic managed by a
full-time NP within the pharmacy. The metabolic clinic
was initiated to improve monitoring and manage the
metabolic side effects of mental health medications, spe-
cifically atypical antipsychotics. This multi-professional
service involves in-pharmacy collaboration between the
NP and pharmacy staff, as well as external collaboration
with patients’ psychiatrists and case managers from a
nearby government mental health service. The metabolic
clinic is funded by an independent benefactor and under-
pinned by a Memorandum of Understanding with the
government mental health service, to manage up to 300
patients. At the time of the evaluation, 12 months
following its initiation, 44 patients had been managed by
the metabolic clinic.
Previous evaluation of disease state management ser-
vices mainly reported patient satisfaction, clinical indica-
tors and quality of life [17–20]. Our evaluation draws on
these principles, as well as the integration of ‘good prac-
tice’ standards and guidelines, tailored to the service [21].
This service evaluation was endorsed by the pharmacy
manager as a quality assurance exercise and an opportun-
ity to reflect on plans for service expansion.
As such, the aim of this project was to conduct a ser-
vice evaluation of the metabolic clinic for mental health
patients. Specific objectives were to:
1. Develop a service evaluation framework to describe
the metabolic clinic service, and facilitate analysis
and critique of the service.
2. Evaluate the service against the developed
framework, and identify areas requiring
improvement.
Methods
Low-risk ethical approval was granted by the Human
Research Ethics Committee of Curtin University,
Australia (approval number: PH-02-14), for access to
pharmacy and de-identified patient data, and for inter-
views with pharmacy staff. This research was exploratory
and involved two stages.
Stage one: development of a health service evaluation
framework
Assessment of the integrative pharmacy-based service re-
quired the development of a tailored service evaluation
framework. Indicators were compiled from a number of
sources involving published literature in the area of quality
healthcare, and pharmacy good practice standards and
guidelines relating to primary mental healthcare. ‘Process’
indicators were included to evaluate service delivery pro-
cesses and procedures [17, 22, 23], ‘outcome’ indicators
were included to evaluate patient health records [17, 18],
and ‘quality’ indicators focused on the significance of care
delivered via the service to potentially improve the pa-
tients’ health outcomes [20, 24]. All members of the re-
search team concurred on the categorisation of indicators.
Stage two: evaluation of service elements against the
framework
The evaluation comprised two phases to evaluate the
existing service against the framework: interviews with
the pharmacy staff members, and an evaluation of the
metabolic clinic patients’ records.
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Staff interviews
Semi-structured qualitative interviews were conducted
with pharmacy staff during March 2014, to obtain insight
into the running of the metabolic clinic to facilitate analysis
of the service procedures and staffing contributions. Inter-
views were identified as a more practical solution for en-
gaging with individual staff members with different work
rosters compared to a focus group(s); this method also
allowed tailoring of questions to staff members’ roles in the
metabolic clinic. All staff with some involvement with the
metabolic clinic, and who worked during the operational
hours of the metabolic clinic service, were included. Two
interview guides were developed by the research team and
validated by the pharmacy owner, who ensured relevance
of the questions; suggested changes were incorporated.
The interview guide for the pharmacists (Additional file 1)
and (Additional file 2) NP comprised 10 questions focusing
on the processes and operation of the metabolic clinic ser-
vice, the role of staff members and potential improvements
to the service (i.e. process and quality indicators). The
questions were slightly modified for pharmacy assistants to
reflect their scope of practice. The use of open-ended ques-
tions and prompts encouraged staff to detail their experi-
ences and explore ideas, and generated subjective and
objective data. Interviews were conducted within the phar-
macy premise, with signed consent for audio recording.
Recordings were transcribed and annotated electronic-
ally by the primary researcher, with data categorised
under the relevant process or quality indicator. Content
analysis was confirmed by the collaborating researchers,
and data were reported descriptively, supported by de-
identified quotations.
Patient data collection
A spreadsheet of de-identified patient biometric informa-
tion was provided by the NP to provide insight into out-
come indicators. The spreadsheet was evaluated for the
main parameters that the NP recorded: weight, height,
body mass index, waist circumference, blood pressure and
blood glucose levels, lipid profile, heart rate, respiratory
rate and oxygen saturation. Missing data were annotated
using verbal explanations by the NP. In light of the recent
commencement of the service and number of patients en-
rolled, specific patient cases, based on positive outcomes
achieved, were reported as case studies in lieu of statistical
analysis of within- and inter-patient outcomes data, and to
demonstrate the breadth of the service.
Results
Stage one: Development of the health service evaluation
framework
The evaluation framework (Table 1) comprised 13
process indicators, five outcome indicators and 11 qual-
ity indicators.
Stage two: evaluation of service elements against the
framework
From the pharmacy’s 12 staff members, 10 met the inclu-
sion criteria and consented to participate in an interview.
The two excluded staff members were not employed during
the operational hours of the metabolic clinic. Participants
comprised six pharmacists, one NP and three pharmacy as-
sistants. Interviews ranged from 20 to 40 min each (mean
30 min).
The following sections report the process, outcome
and quality indicators relating to the metabolic clinic
service. Process and quality data were derived from the
interviews, while outcome data were derived from the
patients’ biometric data. No additional categories were
identified for inclusion in the evaluation framework
during the analysis. Paucity of patient outcomes data
meant a number of outcomes indicators were unable to
be assessed.
Process indicators
Data provided by pharmacy staff directly addressed six of
the 12 process indicators (Table 2). The pharmacy man-
ager described the target patient group as patients pre-
scribed atypical antipsychotics; these patients received the
metabolic clinic service free of charge, as per the fund-
ing arrangement. Non-government mental health pa-
tients were required to make a payment of AUD$25 per
consultation.
The metabolic clinic was overseen by the pharmacy
manager, who monitored patient progress, ensured the
smooth running of the service and evaluated six-monthly
reports received from the NP. One of the pharmacists
conducted promotional presentations, mainly at the gov-
ernment mental health service and a residential care facil-
ity, to ensure health professionals and patients were aware
of the clinic and its relevance to patients’ health. All phar-
macy staff were involved in referring mental health pa-
tients they considered at risk of adverse medication effects
to the clinic.
Staff members were of the opinion that official paper-
work was a barrier to patient management. Initially, the
pharmacy provided referral forms to be completed by the
staff at the government mental health service to introduce
patients to the pharmacy service, but these did not assist
in the pharmacy workflow.
Any adjustments to mental health patients’ therapy by
the staff at the government mental health clinic, identified
during dispensing or other communications with pre-
scribers, were annotated by pharmacists in patient-specific
files kept in a designated area within the dispensary.
Changes to the patients’ medications were reportedly
common and were recorded manually in the files and in
the dispensing software at the time of dispensing, so all
pharmacists were able to view changes. The NP recorded
Maulavizada et al. BMC Health Services Research  (2016) 16:146 Page 3 of 7
patient biometric data in a spreadsheet, and other consult-
ation information in the Best Practice® software kept in
the metabolic clinic.
Quality indicators
Interview data addressed six of the 11 quality indicators
(Table 3). To uphold privacy and confidentiality require-
ments, patients were required to sign a consent form
when initiating with the metabolic clinic. In terms of data
security, the information recorded in the Best Practice®
software was password protected. With the permission of
the NP, the pharmacy manager was, however, able to ac-
cess patient information in the event of an emergency.
Patient assessment was based on biometric parame-
ters. Generally, the first set of blood tests requested
common haematological parameters, and depending on
the results, the NP followed up with more specific path-
ology orders. A vitamin D test was routinely ordered for
all patients, and depending on initial screening, iron levels
would be tested, regardless of the patient’s gender. Age-
appropriate tests were also ordered; for example, an over-
weight male over 50 years of age would also undergo a
Prostate Specific Antigen test.
Patients’ mental health status was assessed through
various communication and observation strategies, with
staff members noting their emotional states and whether
the patient appeared to comprehend information pro-
vided by staff. Pharmacists managed issues within their
Table 2 Process indicators
Process Indicators Examples
Patient initiation with the
metabolic clinic i.e. through the
government mental health clinic
Predominantly patients on atypical
antipsychotics
Enrolment process No official paper work existed in
initiating patients into the metabolic
clinic service
Consultation fee (eligibility for
funded services vs fee-for
service)
Mental health patients on atypical
antipsychotics received the service




Patients were referred to the
Metabolic Clinic Service via staff at
the government mental health
service (psychiatrists, case managers)
Service components provided
by nurse practitioner vs
pharmacist vs pharmacy
assistant
Proprietor oversaw the operation of
the metabolic clinic. The pharmacist
who was next in charge was involved
in promotional activities at the
government mental health clinic.
All staff were actively involved in
referring patients to the metabolic
clinic
Mode of documentation Patient biometrics were recorded in
an Excel spreadsheet. The NP used
the Good Practice® software to
record information relating to
consultations. Changes relating to
medication and/or dosage were
handwritten in patient specific files
Table 1 Metabolic risk health service evaluation framework
Process Indicators [17, 22, 23] Outcome Indicators [17, 18] Quality Indicators [20, 21, 24]
• Patient initiation with the metabolic clinic
i.e. through the government mental health
service
• Enrolment process
• Case load, i.e. how many patients can be
managed,
workload implications, time per consultation
• Management of patients’ issues at the lowest
appropriate level (i.e. lowest primary health
care level and minimum level of service)
• Service components provided by nurse
practitioner
vs pharmacist vs pharmacy assistant
• Process involved in outcomes reporting [17]
• Referrals and associated communication [23]
• Follow-up of the patient [23]
• Consultation fee (eligibility for funded services
vs fee-for service)
• Data recorded at different points of
consultation [22]
• Baseline data collection [22]
• Mode of documentation [23]
• Monitoring of patient improvement and
evaluation of progression [21]
• Qualitative data (free-text notes, reflections)
[18]
• Patient compliance with medication,
relative to adverse effects experienced,
pill counting and dispensing or supply
intervals [18]
• Improvement in overall health status of
patient (physical and mental health)
• Data collected (e.g. biometric parameters,
subjective assessments, patients’ concerns)
[17]
• Review of the data/readings obtained [18]
• Patient privacy and confidentiality [21]
• Treatment plan customisation for each
patient [20]
• Level of patient assessment. Is it only based
on improving physical symptoms (confirmed
by lab tests), or does it also include
psychological and emotional improvement?
[20, 24]
• Patient education regarding their condition,
treatment and medication side effects [20]
• Simplicity of information (verbal and written)
provided to patients (review sources of
information) [20]
• Up-to-date record keeping [20]
• Level of pharmacists’ communication with
other health professionals [20, 21]
• Staff understanding that mental health patients
may feel stigmatised and hence
treat patients in an understanding manner
(staff completing training specific to mental
health) [20]
• Pharmacist involvement in professional
development courses to enhance knowledge
in providing the disease state management
service [21]
• Promotional activities undertaken in relation
to mental health, as a form of encouragement
for current patients [20]
• Improvements in the metabolic clinic service
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scope and confidence level, and referred patients to rele-
vant professionals. Overall, the pharmacists viewed their
communication with other health professionals, with
specific relevance to the staff at the government mental
health service, as effective and productive. Pharmacy
staff used the mobile telephone numbers of the psychia-
trists and case managers in emergencies, while other
modes of contact were used to discuss less-urgent pa-
tient matters. One of the pharmacists was also a liaison
pharmacist with the government mental health service,
and was in frequent contact with the facility. Patient
education facilitated medication adherence, and staff
adopted a holistic approach by also addressing the im-
portance of healthy lifestyles and monitoring.
One area for improvement identified was a need for
promotion of the metabolic clinic at other mental health
clinics within close proximity of the pharmacy, to increase
health professional and patient awareness. A second short-
coming was the lack of communication between the phar-
macists’ dispensing software and the NP’s Best Practice®
software, with the latter software the same as that utilised
by many prescribers. When the NP’s medication records
were not current, the NP checked the dispensing software
for recent changes. This was identified as not only incon-
venient, but potentially compromising patient care. The
pharmacy was in the process of implementing new
software to integrate the dispensing and the NP’s systems.
Furthermore, the handwritten annotations regarding pa-
tient progress by pharmacists’ in patient files may increase
the likelihood of human error. Handwriting was recog-
nised as a risk for misinterpretation of medication names,
dosages and frequencies. Hard-copy patient files may also
be misplaced in a busy work environment.
Outcome indicators
The patient spreadsheet contained biometric information
for 20 patients for the period November 2013 (com-
mencement of the current service contract) to March
2014 (close of data collection). Data for 24 patients were
not provided, in accordance with privacy requirements
under a previous service agreement. Positive trends were
noted for the 20 patients, although the number of follow-
up visits to the clinic (and hence, data) varied between pa-
tients. Improvements in physical health risk indicators
were observed for most patients during the operation of
the clinic.
Three patient cases illustrative of those with clinically-
significant outcomes over the short follow-up period are
presented in Table 4.
Discussion
The novel pharmacy service evaluated was established in
2013, and was still undergoing development at the time
of the study. The service was introduced in the absence
of an evaluation framework; as such, this independent
review of systems and processes was timely for reflection
and quality improvement.
The evaluation of this metabolic clinic service, which
represents a unique model of collaboration between a NP
and pharmacists, suggests potential for the development
of other multi-disciplinary health services in community
pharmacies. The metabolic clinic was predominantly oper-
ated and managed by the NP, with pharmacists mainly
involved in routine medication management and referral
of patients to the service. In Australia, registered NPs have
formalised roles allowing them to prescribe certain
government-remunerated medication, order pathology
tests and administer injections, thereby enabling NPs to
manage patients in collaboration with other health profes-
sionals [25]. The pharmacists played a significant role in
facilitating patient health literacy and educating them
about their medication in order to improve adherence,
complementing the NP’s role. This multi-professional ap-
proach allowed both the NP and pharmacists to provide
patient care in their own fields of expertise, using a holis-
tic and collaborative model of care.
Australian trials over the past decade have revealed
positive patient outcomes in community pharmacist-led
management of asthma [5], diabetes [6] and hyperten-
sion [7]. Common features of these multi-site studies




Patients were required to sign a
consent form before signing up
with the metabolic clinic service
The level of patient assessment.
Is it only based on improving
physical symptoms (confirmed
by lab tests), or does it also
include psychological and
emotional improvement?
Metabolic clinic assessments were
based on physical parameters, such
as blood pressure, blood glucose
levels, lipid profile and weight
Patient education regarding
their condition, treatment and
medication side effects
Staff addressed medication compliance
issues, by educating the patient on the
importance of his/her medication and
its relevance to his/her health
Pharmacist involvement in
professional development
courses to enhance knowledge
in providing the disease state
management service
Pharmacists were actively involved
in professional development courses,
such as Mental Health First Aid
The level of pharmacists’
communication with other
health professionals
Pharmacists were in regular contact
with psychiatrists and staff members
at the government mental health clinic
Improvements to the metabolic
clinic service
The study pharmacy required further
promotion of its service for greater
patient numbers.
Integration between the NP’s software
and pharmacists dispensing software
was required for up-to-date patient
medication data
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were the leadership of pharmacists in developing a
therapeutic relationship with patients at risk of compli-
cations, collaborative identification of therapeutic goals,
and provision of counselling and referrals to assist pa-
tients in achieving these goals. In none of these studies
was a NP (or any other non-pharmacist health profes-
sional) employed in the pharmacy to collaborate in pa-
tient management. This collaboration, drawing on the
unique scope of practice of NPs, is proposed to further en-
hance ambulatory management of patients with chronic
conditions. While it was not feasible to attribute ‘cause
and effect’ of the NP’s interventions in the three cases pre-
sented, the patients’ progress and commitment suggest
impact of the NP’s role over a relatively short period.
The pharmacists’ role in referral to the metabolic clinic
and routine medication management complemented the
role of the NP. Pharmacy assistants were primarily in-
volved in referring ‘at-risk’ patients to the pharmacists for
consultation. The NP took responsibility for the majority
of patient management, documentation and referrals.
There were no time restrictions on the NP to complete
consultations, which facilitated patient-centred and quality
care. Collectively, this teamwork appeared effective, and
with an appropriate service contract, could be applied to
other settings and health conditions. Areas for improve-
ments highlighted by the evaluation – the need for inte-
grated software and promotion of the service – were
already recognized by the participants.
There were limitations in our method of evaluation.
This study only evaluated patient data over a five-month
period, as previous data were unavailable for analysis. In
addition, the study did not incorporate economic evalu-
ation, due to the confidentiality of business data. However,
our early-stage evaluation has been adopted as part of the
pharmacy’s culture of continuous quality improvement,
which may include economic evaluation. The funding
arrangement with the independent benefactor ensured fi-
nancial viability for 1000 patients and relieved the phar-
macy manager of financial pressure and concerns about
financial viability of the metabolic clinic.
In relation to the interview process, reporting bias
from the staff members could not be discounted. All
staff involved in the service, regardless of their role in
instigating or otherwise providing the service, were in-
cluded and were encouraged to critically reflect on its
operation. As with all qualitative research, the back-
ground and perspectives of the researcher may have an
impact on analysis of the data. However, all members of
the research team were involved in the analysis pre-
sented here.
We now offer this evaluation framework as a starting
point for evaluation of other patient-focused services,
acknowledging that the number of criteria could be re-
duced or adapted to other settings, and resource indica-
tors could be added to reflect physical requirements for
service establishment and provision. The study phar-
macy was deemed to be providing an overall effective
service in relation to all three indicators, despite the
interview data mapping to only a portion of the con-
stituent criteria.
Table 4 Patient cases
Weight reduction, improved blood pressure
control
Improved lipid profile Increased physical activity and smoking
cessation
Mrs X: 30 years old Mr Y: 42 years old Mr Z: 71 years old
Data were available from the patients’ second
through sixth appointment. During this period,
the patient was able to implement an effective
diet and exercise program with the assistance
of the NP, which allowed her to lose weight
and reduce her blood pressure. She lost six
kilograms, and her blood pressure reduced from
131/88 to 125/75. Her waist circumference
reduced from 133 cm to 120 cm. While she had
not incorporated extensive changes to her lifestyle,
simply being able to make small adjustments in
her habits has enabled improvements. These small
changes include walking her dog at a faster rate,
stepping up and down a curb and making better
choices for breakfast, such as smoothies. Whilst
she may still opt for something sugary, it is now
a matter of eating a small bar of chocolate rather
than a bag of lollies. This case portrays an ideal
case of a patient who has been able to incorporate
small changes, and achieve results. She visited the
pharmacy frequently and consulted with the NP.
This indicates the significance of the metabolic
clinic, as well as the patient-centred service
provided by the pharmacy.
Mr Y was identified as being overweight,
requiring a diet and exercise program.
A blood test result revealed high lipid levels,
with total cholesterol being 7.9 mmol/L and
triglycerides being 5.7 mmol/L. As a result,
the NP initiated him on rosuvastatin (Crestor®).
This medication reduced his total cholesterol
to 5 mmol/L and triglycerides to 2.8 mmol/L.
Six months later, the patient decided to cease
the rosuvastatin (Crestor®), as he did not
understand why there was a need for him to
continue. Following this, another blood test
result showed raised levels, with total cholesterol
being 8.6 mmol/L and triglycerides 6.2 mmol/L.
After the patient was shown these results, he
re-commenced rosuvastatin (Crestor®). It was
hoped that he would return for future
consultations and blood tests. In this case, the
NP was able to educate the patient on the
importance of his medication, by explaining his
test results and reasoning why those values had
increased, which proved to be beneficial advice
for the patient.
After being admitted to hospital, possibly
with chest pain or a myocardial infarction,
Mr Z was encouraged to change his lifestyle,
with the assistance of the NP. In a period of
two months, his systolic blood pressure had
risen from 140/100 to 153/78. In the space of
one month, effective lifestyle changes allowed
for his blood pressure to reduce to 112/54.
The NP described him as an extremely
motivated individual; he would come into the
pharmacy more frequently than his hospital
visits. The major change he incorporated into
his life was increasing his physical activity by
cycling. After his emergency visit to the
pharmacy, he also undertook smoking
cessation with the support of the NP.
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Conclusions
This service evaluation met its objectives of developing an
evaluation framework that may be refined and applied to
patient-focused health management services. The subse-
quent evaluation identified that the metabolic clinic service
was meeting key indicators including process, outcomes
and quality indicators, and the positive patient outcomes
may facilitate further funding from the independent bene-
factor. Areas requiring improvement, namely electronic
data management and increased promotion, were identi-
fied. Awareness of these limitations and practical solutions
will ensure the service is positioned for regular evaluation
and allow for expansion.
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